ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• RBQM For Decentralized Trials: Two Key Areas Of Focus To Reduce Your Risk

  This article takes a more in-depth look at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ in ICH-GCP E6 R2 to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.

• The Vendor Selection Blunder: An Expensive Oversight In Clinical Trials

  Vendor selection isn’t just procedural — it shapes trial outcomes. Even with a solid process, missteps can ripple through timelines, budgets, and team morale. Choose wisely.

• Data Quality And Monitoring In Clinical Trials: Reducing Errors And Ensuring Compliance

  Clear data ownership and tailored reporting tools reduce errors and manual reconciliation, keeping trial data accurate and audit-ready.

• Your CRAs Aren't Monitoring. They're Managing Workarounds.

  CRA productivity rises when monitoring shifts from manual tasks to streamlined access, standardized workflows, and proactive oversight — freeing time for engagement, data quality, and patient safety.

• Oncology Preferences From Patients And Caregivers On Trial Tech

  Delve into the preferences of patients and caregivers in the field of oncology, specifically regarding eConsent, telehealth, wearables, and other digital technologies.

• Castor Services
• What Universalized Terminology Means For Decentralized Research

  Many DCT stakeholders have attempted to release terminology guides as it relates to their own dealings, however, there had never been a wide range of universalized DCT terms until now. 

• Own Your Data, Accelerate Your Cure

  Move from passive donor to active innovator. Explore how patient communities are building their own research infrastructure and using AI to bypass traditional barriers to drug development.

• Bringing Clinical Research To The Patient Using Patient-Centric Tech

  By fostering daily interactions between patients and technology, these smart hubs offer a sustainable approach to ensuring the success and integrity of clinical trials in an evolving landscape of drug development.

• Fujirebio Increases Study Agility By Streamlining Clinical Operations And Data Management Process

  Fujirebio’s fast-growing U.S. Clinical R&D team was preparing for shorter studies with higher complexity. Traditional methods using paper and spreadsheet trackers were no longer adequate to meet quality goals. Learn how the group increased its agility and readiness with LifeSphere Clinical EDC and CTMS tools.